Seven Eight Capital, LP Ligand Pharmaceuticals Inc Transaction History

Seven Eight Capital, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 15, 2019	SELL	$105.93 - $142.47 $2 Million - $2.69 Million	-18,900 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$128.36 - $272.13 $2.43 Million - $5.14 Million	18,900 New	18,900 $2.57 Million
Q3 2018 Oct 18, 2018	SELL	$211.18 - $274.49 $274,534 - $356,837	-1,300 Closed	0 $0
Q2 2018 Aug 07, 2018	BUY	$150.77 - $207.98 $196,001 - $270,374	1,300 New	1,300 $269,000
Q4 2017 Feb 12, 2018	SELL	$128.36 - $147.04 $192,540 - $220,560	-1,500 Closed	0 $0
Q3 2017 Oct 16, 2017	BUY	$120.91 - $137.94 $181,365 - $206,910	1,500	1,500 $204,000

277

18.5M

30.8K

5.2K

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $1.83B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

Get notified when there are updates to the investment portfolio of Seven Eight Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Seven Eight Capital, LP with notifications on news.